Introduction:
Metabolic Syndrome (MetS) is an endocrinopathy that starts with insulin resistance, accompanied by a range of systemic disorders such as glucose intolerance, diabetes mellitus (DM), abdominal obesity, dyslipidemia, hypertension (HT), and coronary artery disease (CAD) [1]. MetS is one of the most important health problems with increasing prevalence and awareness. Due to the increased prevalence of MetS in society, the number of studies on this subject has increased. The prevalence of MetS, which is considered to be an important health problem in developed and developing countries, varies depending on age and gender [2, 3].
Although MetS was previously thought to cause only cardiovascular problems, new data reveal that it occurs with some urological disorders. The prevalence of erectile dysfunction, infertility, stone disease, overactive bladder, benign prostatic hyperplasia has also increased in these patients. At the same time, its relationship with malignancy by causing angiogenesis and oxidative stress due to baseline insulin resistance has been revealed. It has been observed to increase the incidence and progression of cancers. MetS has also caused an increase in the incidence of prostate cancer and Renal Cell Carcinoma (RCC) [4-7].
RCC accounts for 2-3% of all adult malignant masses and for 85-90% of malignant tumors of the kidney. RCC is the highest mortality rate among the urological malignancies. Although RCC ranks third after prostate and bladder cancer among urological cancers, it accounts for 40% of deaths due to urinary system cancers. Knowledge of the etiology of RCC plays an important role in understanding the onset of histological cancer and its progression to invasive cancer [8, 9]. Although there is no definite data that MetS components are effective in the development of RCC, some studies have reported that especially high-calorie dietary habits and obesity have some roles in the development of RCC and some studies have reported that DM, HT, and hypertriglyceridemia are important in the development of RCC [10-13].
This study aimed to reveal which MetS components have more clinical significance to compare kidney tumor characteristics of patients with and without MetS and to determine clinically significant risk factors for patient groups.